A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer-Reference-Cited by-同舟云学术

A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer

Published:2017-12 Issue: Volume:267 Page:191-202
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Vogus Douglas R.,Evans Michael A.,Pusuluri Anusha,Barajas Alexandra,Zhang Mengwen,Krishnan Vinu,Nowak Maksymilian,Menegatti Stefano,Helgeson Matthew E.,Squires Todd M.,Mitragotri Samir

Funder

National Science Foundation

NIH

NSF Graduate Research Fellowship

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference61 articles.

1. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer;Devita;Cancer,1975

2. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer;Tkaczuk;Clin. Ther.,2009

3. Single agent versus combination chemotherapy for metastatic breast cancer;Carrick;Cochrane Database Syst. Rev.,2009

4. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies;Chou;Pharmacol. Rev.,2006

5. Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling;Oliveras-Ferraros;Int. J. Oncol.,2008

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rational design of a poly-L-glutamic acid-based combination conjugate for hormone-responsive breast cancer treatment;Journal of Controlled Release;2024-11

2. In situ administration of STING-activating hyaluronic acid conjugate primes anti-glioblastoma immune response;Materials Today Bio;2024-06

3. New insights into polysaccharide-based nanostructured delivery systems in breast cancer: Possible application of antisense oligonucleotides in breast cancer therapy;International Journal of Biological Macromolecules;2024-06

4. Non-vesicular nanocarriers for breast cancer management: current advances, challenges, and future perspective;International Journal of Polymeric Materials and Polymeric Biomaterials;2024-04-24

5. Subcutaneous drug delivery from nanoscale systems;Nature Reviews Bioengineering;2024-03-19